Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroids improving quality of life

Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer

Comment: It is essential to identify the BRCA gene in pancreatic cancer patients allowing them to be treated with an oral agent

AXL inhibitor bemcentinib in combination with chemotherapy exerts anti-leukaemic activity in AML patients

PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer

Subcutaneous versus intravenous daratumumab administration in patients with relapsed or refractory multiple myeloma

Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment

Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer

Latest in ovarian cancer treatment

Optimal use of tyrosine kinase inhibitors as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukaemia

Master pathways and targets in T cell acute lymphoblastic leukaemia